Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revvity, Inc. Common Stock (NY: RVTY )

123.59 +0.43 (+0.35%)
Streaming Delayed Price Updated: 10:47 AM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revvity, Inc. Common Stock

< Previous 1 2 3 4 Next >
Revvity (NYSE:RVTY) Reports Q4 In Line With Expectations
Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year revenue... 
Via StockStory
Friday's pre-market session: top gainers and losers in the S&P500 index
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
From Revvity
Via Business Wire
Earnings Scheduled For January 31, 2025
Via Benzinga
(RVTY) - Analyzing Revvity's Short Interest
Via Benzinga
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Forecasting The Future: 7 Analyst Projections For Revvity
Via Benzinga
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
From Revvity
Via Business Wire
These Analysts Revise Their Forecasts On Revvity Following Q3 Results
Via Benzinga
Assessing Revvity: Insights From 8 Financial Analysts
Via Benzinga
Looking Into Revvity's Recent Short Interest
Via Benzinga
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
From Revvity
Via Business Wire
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
From Revvity
Via Business Wire
Revvity to Present at J.P. Morgan Healthcare Conference
From Revvity
Via Business Wire
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA upgrades Danaher and Revvity, predicting a mixed but improving outlook for life sciences tools in fiscal year 2025 amid ongoing market challenges. 
Via Benzinga
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
From Revvity
Via Business Wire
Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
From Scale Biosciences
Via Business Wire
Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference
From Revvity
Via Business Wire
Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation
From Revvity
Via Business Wire
Revvity Announces Financial Results for the Third Quarter of 2024
From Revvity
Via Business Wire
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories
From Revvity
Via Business Wire
Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report
From Revvity
Via Business Wire
Revvity To Hold Earnings Call on Monday, November 4, 2024
From Revvity
Via Business Wire
Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene
From Revvity
Via Business Wire
Revvity to Present at Upcoming Investor Conferences
From Revvity
Via Business Wire
Wall Street Rises Ahead Of Big Tech Earnings, Fed Meeting; Tesla Rebounds, Oil Prices Drop To 7-Week Lows: What's Driving Markets Monday?
Wall Street opened higher at the start of a data-heavy week, with traders adopting an optimistic tone ahead of crucial earnings reports and economic events. 
Via Benzinga
Topics Economy
Exposures Interest Rates
RVTY Stock Earnings: Revvity Beats EPS, Beats Revenue for Q2 2024
RVTY stock results show that Revvity beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Life Science Firm Revvity Lifts Annual Profit Forecast On Strong Q2 Performance
Revvity reported Q2 sales of $691.69 million, surpassing estimates, with adjusted EPS of $1.22. Life Sciences revenue fell 7%, while Diagnostics sales rose 1%. Updated 2024 guidance includes sales of... 
Via Benzinga
Revvity Announces Financial Results for the Second Quarter of 2024
From Revvity
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.